Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer: Dream or reality?

Orazio Caffo, Andrea Lunardi, Chiara Trentin, Francesca Maines, Antonello Veccia, Enzo Galligioni

Research output: Contribution to journalArticle

Abstract

The availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidence of possible cross-resistance has reinforced the debate concerning the best sequence to use in order to maximise the benefit. Furthermore, the situation is further complicated by the possibility of administering new hormonal agents to chemotherapy-naïve patients, and novel chemotherapeutic agents to hormone-sensitive patients. This article critically reviews the available data concerning the sequential use of new drugs, and discusses the real evidence concerning their optimal positioning in the therapeutic strategy of metastatic castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)1301-1308
Number of pages8
JournalCurrent Drug Targets
Volume17
Issue number11
Publication statusPublished - Sep 1 2016

Fingerprint

Castration
Prostatic Neoplasms
Pharmaceutical Preparations
Chemotherapy
Survival
Availability
Hormones
Clinical Trials
Drug Therapy
Therapeutics

Keywords

  • Abiraterone acetate
  • Cabazitaxel. enzalutamide
  • Castration-resistant prostate cancer
  • Docetaxel
  • First-line
  • Second-line
  • Sequence

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Caffo, O., Lunardi, A., Trentin, C., Maines, F., Veccia, A., & Galligioni, E. (2016). Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer: Dream or reality? Current Drug Targets, 17(11), 1301-1308.

Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer : Dream or reality? / Caffo, Orazio; Lunardi, Andrea; Trentin, Chiara; Maines, Francesca; Veccia, Antonello; Galligioni, Enzo.

In: Current Drug Targets, Vol. 17, No. 11, 01.09.2016, p. 1301-1308.

Research output: Contribution to journalArticle

Caffo, O, Lunardi, A, Trentin, C, Maines, F, Veccia, A & Galligioni, E 2016, 'Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer: Dream or reality?', Current Drug Targets, vol. 17, no. 11, pp. 1301-1308.
Caffo, Orazio ; Lunardi, Andrea ; Trentin, Chiara ; Maines, Francesca ; Veccia, Antonello ; Galligioni, Enzo. / Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer : Dream or reality?. In: Current Drug Targets. 2016 ; Vol. 17, No. 11. pp. 1301-1308.
@article{4957dae1e26242649581d30598cac6c8,
title = "Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer: Dream or reality?",
abstract = "The availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidence of possible cross-resistance has reinforced the debate concerning the best sequence to use in order to maximise the benefit. Furthermore, the situation is further complicated by the possibility of administering new hormonal agents to chemotherapy-na{\"i}ve patients, and novel chemotherapeutic agents to hormone-sensitive patients. This article critically reviews the available data concerning the sequential use of new drugs, and discusses the real evidence concerning their optimal positioning in the therapeutic strategy of metastatic castration-resistant prostate cancer.",
keywords = "Abiraterone acetate, Cabazitaxel. enzalutamide, Castration-resistant prostate cancer, Docetaxel, First-line, Second-line, Sequence",
author = "Orazio Caffo and Andrea Lunardi and Chiara Trentin and Francesca Maines and Antonello Veccia and Enzo Galligioni",
year = "2016",
month = "9",
day = "1",
language = "English",
volume = "17",
pages = "1301--1308",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer

T2 - Dream or reality?

AU - Caffo, Orazio

AU - Lunardi, Andrea

AU - Trentin, Chiara

AU - Maines, Francesca

AU - Veccia, Antonello

AU - Galligioni, Enzo

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidence of possible cross-resistance has reinforced the debate concerning the best sequence to use in order to maximise the benefit. Furthermore, the situation is further complicated by the possibility of administering new hormonal agents to chemotherapy-naïve patients, and novel chemotherapeutic agents to hormone-sensitive patients. This article critically reviews the available data concerning the sequential use of new drugs, and discusses the real evidence concerning their optimal positioning in the therapeutic strategy of metastatic castration-resistant prostate cancer.

AB - The availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidence of possible cross-resistance has reinforced the debate concerning the best sequence to use in order to maximise the benefit. Furthermore, the situation is further complicated by the possibility of administering new hormonal agents to chemotherapy-naïve patients, and novel chemotherapeutic agents to hormone-sensitive patients. This article critically reviews the available data concerning the sequential use of new drugs, and discusses the real evidence concerning their optimal positioning in the therapeutic strategy of metastatic castration-resistant prostate cancer.

KW - Abiraterone acetate

KW - Cabazitaxel. enzalutamide

KW - Castration-resistant prostate cancer

KW - Docetaxel

KW - First-line

KW - Second-line

KW - Sequence

UR - http://www.scopus.com/inward/record.url?scp=84983749203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983749203&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84983749203

VL - 17

SP - 1301

EP - 1308

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 11

ER -